-
03.25.2020 | Forge Enters into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
Forge Therapeutics announced today that it has entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. The FG-LpxC LUNG program is being developed, with support from CARB-X, to treat hospital-based infections which commonly occur in people with weakened immune systems and chronic lung diseases. Forge is eligible to receive US$190.5M in total payments and potential sales-based payments and royalties upon commercialization of the program. This is the first CARB-X funded program to be the subject of such an agreement with a major pharmaceutical company.
-
03.17.2020 | Coronavirus Surprised The World, But Doctors Have Been Sounding The Alarm On Another Global Health Threat For Years
WGBH | COVID19 surprised the world but scientists have been warning for years about another global health threat. WGBH’s Stephanie Leydon speaks to a patient, Dr. Helen Boucher at Tufts Medical Centre and CARB-X’s Kevin Outterson to examine the threat of drug-resistant bacterial infections and the challenges of developing innovative products to prevent, diagnose and treat them.
-
02.24.2020 | New Genomic Tests Aim to Diagnose Deadly Infections Faster
NEW YORK TIMES | Rapid genomic tests are poised to change the way doctors diagnose and treat bacterial infections, but cost concerns may limit widespread use despite their usefulness. Developers of the some of the devices say that once the genetic sequence of a novel pathogen has been made publicly available, the information could be quickly uploaded and used to identify those infected. NYT Health and Science journalist Andrew Jacobs interviews experts at T2, Day Zero Diagnostics and other companies about the benefits of using these advanced technologies to diagnose serious infections, and the challenges that companies face in getting governments and hospitals to use better technology .
-
02.05.2020 | The Fatally Slow Quest for Next-Gen Antibiotics
MEN’S HEALTH | Many bacteria have stopped responding to the drugs that used to kill them, and drugmakers have stopped responding to alarms about it. Can the system possibly be fixed before the bacteria win? Science writer Sarah Richards examines the high human toll superbugs are taking, the economics of antibiotics, and looks for answers from experts in the field, including BARDA Director Rick Bright.
-
01.27.2020 | The Broken Model of Antimicrobial Resistance: Let’s Talk About Solutions
An expert panel moderated by CARB-X Executive Director Kevin Outterson discusses solutions to the antimicrobial resistance crisis at a session sponsored by Novo Nordisk Foundation during the World Economic Forum in Davos, January 21, 2020. Listen to an interview with Outterson and other experts.
-
01.27.2020 | Tackling antimicrobial resistance on multiple fronts
PHARMA MARKET LIVE | Daniel Berman, Head of Global Health at Nesta Challenges, calls for a new international funding mechanism to be created, one that will be initiated and backed by multiple players, including decision-makers and influencers in pharma and healthcare who know the scale of the AMR challenges we face.
-
01.21.2020 | Why developing new antibiotics is a matter of life and death
NOVO HOLDINGS | In this opinion piece timed to the World Economic Forum Davos 2020, Kasim Kutay, Chief Executive Director of Novo Holdings, says the drought of new treatments for drug-resistant infections will not end anytime soon, unless policy-makers fix the broken antibiotics market.
-
01.17.2020 | Novel Drug Candidate Aims To Tackle Superbug Infections In Cystic Fibrosis Patients
FORBES | In a world where antibiotics are becoming increasingly unsuccessful at treating infections, those who suffer worst are often the sick and the young. Unfortunately, in the case of Cystic Fibrosis, patients often check off both these boxes. The French bio-pharmaceutical company Antabio is developing a way to help these vulnerable patients. This month, Antabio was granted $4.4 million by CARB-X in a second tranche of funding to continue to develop its Pseudomonas Elastase Inhibitor (PEi) program. This is in addition to $2.8 million awarded in 2017. The Antabio program is focused on a novel small molecule candidate that was found to be a potential adjunct treatment for Pseudomonas aeruginosa infections in Cystic Fibrosis patients. Antabio CEO Marc Lemonnier, said: “Its actually a groundbreaking approach, it’s never been done before. I think that’s what CARB-X has recognized and that’s why they are funding.”
-
01.08.2020 | Antabio continues research for lung infection therapy with $4.4 million support from CARB-X
CYSTIC FIBROSIS NEWS TODAY | Biopharmaceutical company Antabio has been awarded $4.4 million by CARB-X in a second tranche of funding to continue its research for a therapy against Pseudomonas aeruginosa lung infections in people with cystic fibrosis (CF). The funding will be used to support Antabio’s Pseudomonas Elastase Inhibitor (PEi) program, which is seeking to develop a small molecule to stop the action of the LasB elastase protein. That protein, made by the bacteria Pseudomonas aeruginosa, causes damage and inflammation to lung tissue, and prevents the immune system from defending against the bacteria effectively.
-
01.05.2020 | Antibiotic Makers Struggle, Hurting War on Superbugs
WALL STREET JOURNAL | The world desperately needs new antibiotics to tackle the rising threat of drug-resistant superbugs, but there is little reward for doing so. The companies that have stepped up to the challenge are going bust. Washington has taken notice of the problems, but near-term action remains unlikely. The Disarm Act, short for Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms and introduced in Congress in 2019, would have Medicare pay for certain antibiotics in full. Despite bipartisan support for the bill, progress could be hindered by impeachment proceedings and the coming election. Another idea is a “market entry reward,” a one-time sum paid to companies that launch a new antibiotic. But for now, these improvements are not materializing. “The longer we wait for a sustainable solution, the more companies will die, and the more the earlier pipeline will degrade,” said Kevin Outterson, Professor of Law specializing in the antibiotics market at Boston University. “That’s my real fear.”
-
01.05.2020 | Crisis Looms in Antibiotics as Drug Makers Go Bankrupt
NEW YORK TIMES | At a time when germs are growing more resistant to common antibiotics, Big Pharma has fled the antibiotics field and now start-ups are going belly up, threatening to stifle the development of new drugs. Experts say the grim financial outlook for the few companies still committed to antibiotic research is driving away investors and threatening to strangle the development of new lifesaving drugs at a time when they are urgently needed. The industry faces another challenge: doctors have become reluctant to prescribe the newest medications, limiting the ability of companies to recoup their investment. And in their drive to save money, many hospital pharmacies will dispense cheaper generics even when a newer drug is far superior. “You’d never tell a cancer patient ‘Why don’t you try a 1950s drug first and if doesn’t work, we’ll move on to one from the 1980s,” said Kevin Outterson, the executive director of CARB-X, a government-funded nonprofit that provides grants to companies working on antimicrobial resistance. “We do this with antibiotics and it’s really having an adverse effect on patients and the marketplace.”
Toggle navigation